Comparison of unfractioned and low molecular weight heparin for prophylaxis of coagulopathies in 52 horses with colic: A randomised double-blind clinical trial

Equine Veterinary Journal

Volumn 35, Issue 5, 2003, Pages 506-513

  Feige, K ^a   Schwarzwald, C C ^a   Bombeli, Th ^b  

^a VETSUISSE FACULTY UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Coagulopathies; Colic; Horse; Low molecular weight heparin; Unfractioned heparin

Indexed keywords

DALTEPARIN; HEPARIN CALCIUM; ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING DISORDER; COLIC; CONTROLLED STUDY; DRUG EFFICACY; HEMATOCRIT; JUGULAR VEIN; MEDICAL EXAMINATION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; SPECIES COMPARISON; THROMBIN TIME; ANIMAL; ANIMAL DISEASE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HORSE; HORSE DISEASE; MALE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; COLIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOCRIT; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HORSE DISEASES; HORSES; JUGULAR VEINS; MALE; PARTIAL THROMBOPLASTIN TIME; THROMBIN TIME; TREATMENT OUTCOME;

EID: 0642344582     PISSN: 04251644     EISSN: None     Source Type: Journal    
DOI: 10.2746/042516403775600514     Document Type: Article

References (33)

1. Altman, D.G. (1991) Practical Statistics for Medical Research, Chapman and Hall, London.
2. Barrowcliffe, T.W. and Thomas, D.P. (1988) Low molecular weight heparins: Antithrombotic and haemorrhagic effects and standardization. Acta Chir. Scand., Suppl. 543, 57-64.
3. Boneu, B. (1994) Low molecular weight heparin therapy: Is monitoring needed? Thromb. Haemost. 72, 330-334.
4. Bussey, H.I. (1999) Problems with monitoring heparin anticoagulation. Pharmacother. 19, 2-5.
5. Collignon, F., Frydman, A., Caplain, H., Ozoux, M.L., Roux, Y.L. and Bouthier, J. (1995) Comparison of the pharmakokinetic profiles of three low molecular mass heparins; Dalteparin, Enoxaparin and Nandroparin - administered subcutaneously in healthy volunteers (doses of prevention of thromboembolism). Thromb. Haemost. 73, 630-640.
6. Darien, B.J. (1993) Heparin therapy: rationale and clinical indications. Comp. cont. Educ. pract. Vet. 15, 1273-1276.
7. Duncan, S.G. and Reed, S.M. (1984) Heparin anticoagulant therapy in equine colic. Mod. vet. Pract. 65, 601-605.
8. Duncan, S.G., Meyers, K.M. and Reed, S.M. (1983) Reduction of the red blood cell mass of horses: Toxic effect of heparin anticoagulant therapy. Am. J. vet. Res. 44, 2271-2276.
9. Gardner, S.Y. and Donawick, W.J. (1992) Jugular vein thrombophlebitis. In: Current Therapy in Equine Medicine 3, Ed: N.B. Robinson, W.B. Saunders Co., Philadelphia. pp 406-408.
10. Gerhards, H. (1987) Antithrombin-III-Bestimmung beim Pferd: Referenzwerte und erworbener Antithrombin-III-Mangel. Tierärztl. Prax. 15, 47-55.
11. Gerhards, H. (1991) Low dose calcium heparin in horses: plasma heparin concentrations, effects on red blood cell mass and on coagulation variables. Equine vet. J. 23, 37-43.
12. Gerhards, H. and Eberhardt, C. (1988) Plasma heparin values and hemostasis in equids after subcutaneous administration of low-dose calcium heparin. Am. J. vet. Res. 49, 13-18.
13. Halbmayer, W.M., Feichtinger, C., Schwarz, T., Gschnait, F., Strasser, A., Priesching, A. and Fischer, M. (1990) Ein einfacher Test zur Bestimmung der Anti-Xa-Aktivitat in Plasmen von Patienten nach subkutaner Gabe von Enoxaparin. Wien. Klin. Wochenschr. 102, 408-413.
14. Harenberg, J., Huhle, G., Piazolo, L. and Malsch, R. (1997) Niedermolekulare Heparine. Hautarzt 48, 852-864.
15. Hipp, K.P., Gerhards, H. and Deegen, E. (1991) Heparinprophylaxe katheterbedingter Venenveränderungen beim Pferd. Pferdeheilkunde 7, 3-8.
16. Hirsh, J., Warkentin, T.E., Raschke, R., Granger, C., Ohman, E.M. and Dalen, J.E. (1998) Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114, 489-510.
17. Hofmann, M., Rest, A., Hafner, G. and Tanner, B. (1997) D-Dimer, Thrombin-Antithrombin III-Komplex (TAT) und Prothrombinfragment 1+2 (PTF): Parameter zur Überwachung der Therapie mit niedermolekularem Heparin bei Gerinnungsstörungen. Anästh. 46, 689-696.
18. Johnstone, I.B. and Crane, S. (1986a) Haemostatic abnormalities in horses with colic - their prognostic value. Equine vet. J. 18, 271-274.
19. Johnstone, I.B. and Crane, S. (1986b) Hemostatic abnormalities in equine colic. Am. J. vet. Res. 47, 356-358.
20. Levine, M.N., Hirsh, J., Gent, M., Turpie, A.G., Cruickshank, M., Weitz, J., Anderson, D. and Johnson, M. (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch. int. Med. 154, 49-56.
21. Mahaffey, E.A. and Moore, J.N. (1986) Erythrocyte agglutination associated with heparin treatment in three horses. J. Am. vet. med. Ass. 189, 1478-1480.
22. Monreal, L., Villatoro, A.J., Monreal, M., Espada, Y., Anglés, A.M. and Ruiz-Gopegui, R. (1995) Comparison of the effects of low-molecular-weight and unfractioned heparin in horses. Am. J. vet. Res. 56, 1281-1285.
23. Moore, J.N., Mahaffey, E.A. and Zboran, M. (1987) Heparin-induced agglutination of erythrocytes in horses. Am. J. vet. Res. 48, 68-71.
24. Morris, D.D. (1989) Thrombophlebitis in horses: the contribution of hemostatic dysfunction to pathogenesis. Comp. cont. Educ. pract. Vet. 11, 1386-1395.
25. Morris, D.D. (1998) Diseases of the hemolymphatic system. In: Equine Internal Medicine, Ed: W.M. Bayly, W.B. Saunders Co., Philadelphia. pp 558-601.
26. Nurmohamed, M.T., Cate, H.T. and Cate, J.W.T. (1997) Low molecular weight heparin(oid)s: clinical investigations and practical recommendations. Drugs 53, 736-751.
27. Rosenberg, R.D. (1997) Biochemistry and pharmacology of low molecular weight heparin. Sem. Haematol. 34, 2-8.
28. Rush Moore, B. and Hinchcliff, K.W. (1994) Heparin: a review of its pharmacology and therapeutic use in horses. J. vet. int. Med. 8, 26-35.
29. Schwarzwald, C.C., Feige, K., Wunderli-Allenspach, H. and Braun, U. (2002) Comparison of pharmacokinetic variables for two low-molecular-weight- heparins after subcutaneous administration of a single dose to horses. Am. J. vet. Res. 63, 868-873.
30. Spurlock, S.L. and Spurlock, G.H. (1990) Risk factors of catheter-related complications. Comp. cont. Educ. pract. Vet. 12, 241-249.
31. Stern-Balestra, E., (2000) Bestimmung von löslichen Fibrinkomplexen beim Pferd als Möglichkeit der Diagnostik einer aktivierten Blutgerinnung. Thesis, University of Zurich, Zurich.
32. Traub-Dargatz, J.L. and Dargatz, D.A. (1994) A retrospective study of vein thrombosis in horses treated with intravenous fluids in a veterinary teaching hospital. J. vet. int. Med. 8, 264-266.
33. Weitz, J.I. (1997) Low-molecular-weight heparins. New Engl. J. Med. 337, 688-698.